For a business that seemed to be oft-maligned when it was still part of Abbott Labs (NYSE:ABT), AbbVie (Nasdaq:ABBV) has done pretty well on its own and sports a relatively high valuation amidst its pharma peers. Due in part to the huge influence of one drug (Humira) on AbbVie's results, there's a wider range of outcomes than with many large-cap drugs stocks. Even so, while I think the current valuation is a little steep, I can see numerous ways AbbVie could exceed present expectations and do well for shareholders in the coming years. Good Margins, Despite A Tiny Shortfall In HumiraRevenue at AbbVie rose 4% as reported this quarter, or about 5% on an “operational” basis. Not surprisingly, performance was once again led by Humira, where sales rose almost 13% in constant currency to over $2.6 billion (about 1% short of estimates). At over 55% of sales, Humira clearly continues to dominate AbbVie's performance, though Niaspan was up 10% and ahead of expectations, and Kaletra was likewise stronger than expected. SEE: The Ups And Downs Of BiotechnologyEven with the lack of Humira outperformance, AbbVie's gross margin was substantially higher than expectation – growing four and a half points, and surpassing expectations by three and a half points. AbbVie ended up spending a lot of that in SG&A and R&D, though, and while operating income rose 22% and beat estimates by 5%, the operating margin outperformance was less than a point. Humira Isn't Done YetEven though this market-leading biologic continues to grow nicely, the talk on Humira is almost always negative. Not only are analysts worried that oral drugs like Pfizer's (NYSE:PFE) Xeljanz and Celgene's (Nasdaq:CELG) apremilast will chew into its market share, but also that biosimilars from companies like Mylan (NYSE:MYL) and Hospira (NYSE:HSP) will seriously erode the sales. I think those fears may be a little premature. First, it seems as though biosimilars will in some respects be treated more like new competitors than substitute products, and the pathway to biosimilar approach and market acceptance in the U.S. is still untested. Second, it's worth remembering that Humira has almost twice as many approved indications as rivals like Enbrel (co-markted by Amgen (Nasdaq: AMGN) and Pfizer) and many of its indications are less than 30% penetrated. A Pipeline That's More Than Hep-CGiven the market's obsession with the emerging hepatitis C (HCV) market, I can appreciate why so much attention is focused on AbbVie's HCV prospects. While Gilead (Nasdaq: GILD) still looks like the leader, it would seem that AbbVie will be a very strong second place in what should be a multi-billion dollar market. But as investors have seen all too many times in this market, most recently with Vertex (Nasdaq: VRTX), safety and long-term efficacy issues can appear relatively suddenly in these drugs and I wouldn't count the revenue until its in hand. Beyond hep-C, I think AbbVie's pipeline may be underrated. The company's partnership with Galapagos could bear fruit in the form of AbbVie's own oral RA treatment, and the partnership with Neuroscrine Biosciences (Nasdaq: NBIX) could have a potential blockbuster for endometriosis (and later uterine fibroids), Elagolix, on the market in a few years' time. At the same time, AbbVie has partnered with some quality oncology companies (Bristol Myers (NYSE: BMY) and Roche (Nasdaq: RHHBY) to begin its first serious efforts in oncology. AbbVie also has a very high-reward/high-risk option in neurology. ABT-126 has shown encouraging early efficacy in Alzheimers, and this is a market badly starved of new effective compounds. While it would be unwise to project any future contributions from this drug at this point in time, it could be a multi-billion dollar source of revenue by the end of the decade if AbbVie gets very lucky. SEE: Amgen Puts Onyx Pharmaceuticals In PlayThe Bottom LineAt over 50% of revenue, AbbVie is extremely vulnerable to any disruptions in Humira, and that's a relatively uncommon problem in big pharma, as Amgen, Lilly (NYSE: LLY), and AstraZeneca (NYSE: AZN) have only half as much reliance on any single drug/platform. I consider this to be a fully recognized risk, though, and I see more upside (slower progress with biosimilars, new indications/more market penetration) than downside at this point. All of that said, AbbVie is not strikingly cheap right now. Even with an above-peer long-term revenue growth forecast of more than 3%, it's hard to generate a fair value beyond the low $40s right now. Bulls can reasonably argue that success with pipeline drugs in HCV, endometriosis, cancer, and Alzheimers could make those estimates look much too conservative, but I'd like to see a bigger discount to fair value before buying with my own money. Disclosure – At the time of writing, the author owns shares of Neurocrine Biosciences and Roche.

Related Articles
  1. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  2. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  3. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  4. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  5. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  6. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  7. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  8. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  9. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  10. Stock Analysis

    Are the Brands Millennials Love a Good Buy?

    Millennials make up a very big — and thus important —c onsumer generation. So if they love a brand, its stock is likely to outperform, right?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center